BSCC Pharm 101 basic pharmacology

Pharm 101: Rocuronium

ACEM Primary Pharmacology of Rocuronium: the Pharmacokinetics; Pharmacodynamics; Clinical uses; Reversal

Class

Paralytic agent

Pharmacodynamics
  • Non-depolarising steroid neuromuscular blocking agent used as a paralytic in rapid sequence induction
  • At low doses, acts predominately as a competitive inhibitor of Acetylcholine at nicotinic receptors
  • At higher doses, can enter the pore of the ion channel causing greater neuromuscular blockade
Pharmacokinetics
  • Undergoes rapid distribution
  • Highly ionised therefore small volume of distribution 0.1L/kg
  • Onset of action: 45-60 seconds
  • Intermediate acting: duration of action 20-35 minutes
  • Metabolism: liver
  • Elimination: liver (75-90%) and kidney
Clinical uses
  • Rapid Sequence Induction (RSI)
    • Dose 1.2mg/kg (accepted range 0.9-1.2mg/kg)
  • Clinical effects:
    • Initially motor weakness followed by skeletal muscles becoming flaccid and unexcitable to electrical stimulation
    • Larger muscles (e.g. abdominal, trunk, diaphragm) are more resistant to neuromuscular blockade and recover more rapidly than smaller muscles (e.g. facial, foot, hand)
    • Diaphragm is the last muscle to be paralysed
Sugammadex
  • Sugammadex is a modified cyclodextrin antidote used for rapid reversal of rocuronium and vecuronium
  • Binds tightly to rocuronium in a 1:1 ratio, and this complex is excreted unchanged in the urine
  • This decreases free plasma concentration and establishes a concentration gradient for rocuronium to diffuse away from the neuromuscular junction back into circulation for further binding to free sugammadex
  • Dosing varies for desired reversal effects:
    • 2mg/kg: reversal of shallow neuromuscular blockade
    • 4mg/kg: reversal of deeper blockade
    • 16mg/kg: immediate reversal following administration of single dose 1.2mg/kg rocuronium
  • Adverse effects:
    • Anaphylaxis in 0.3% of patients receiving 16mg/kg dosage
    • Hypersensitivity reactions are common
    • Bradycardia (may progress rapidly to cardiac arrest)
    • Coagulopathy: 25% elevation of APTT and PT/INR values lasting up to one hour
Further Reading

Pharmacology 101

Top 200 drugs

Dr Robert Buttner LITFL Author

MBBS FACEM DDU (Emergency) CCPU. Emergency Physician in Melbourne, Australia. Co-Ultrasound Lead for Emergency Medicine at The Alfred Hospital. Special interests in diagnostic and procedural ultrasound, medical education, and ECG interpretation. Editor of the LITFL ECG Library.

Share your love
Robert Buttner
Robert Buttner

MBBS FACEM DDU (Emergency) CCPU. Emergency Physician in Melbourne, Australia. Co-Ultrasound Lead for Emergency Medicine at The Alfred Hospital. Special interests in diagnostic and procedural ultrasound, medical education, and ECG interpretation. Editor of the LITFL ECG Library.

Articles: 273

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.